Income Statement
VERA THERAPEUTICS, INC.
VERA
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Revenue
|
- | - | - | - | - |
|
Cost of Revenue
|
- | - | - | - | - |
|
Gross Profit
|
- | - | - | - | - |
|
Operating Expenses
|
315.47 | 167.17 | 102.01 | 90.90 | 34.40 |
|
Research & Development
|
215.26 | 126.17 | 78.23 | 68.99 | 22.48 |
|
Selling, General & Administrative
|
100.22 | 41.00 | 23.79 | 21.91 | 11.92 |
|
Other Operating Expenses
|
- | - | - | - | - |
|
Operating Income
|
-315.47 | -167.17 | -102.01 | -90.90 | -34.40 |
|
Non-Operating Income
|
15.86 | 15.02 | 6.02 | 1.85 | 1.79 |
|
Interest Income
|
24.48 | 20.71 | 7.98 | 1.75 | 0.02 |
|
Interest Expense
|
- | - | 3.79 | 0.99 | 0.02 |
|
Other Non-Op Income / Expense
|
- | - | - | - | - |
|
Income Before Tax
|
-299.61 | -152.15 | -95.99 | -89.06 | -32.61 |
|
Income Tax Expense
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Non-Controlling Interest
|
- | - | - | - | - |
|
Net Income
|
-299.62 | -152.15 | -95.99 | -89.06 | -32.61 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - |
|
EBITDA
|
-315.01 | -167.07 | -102.01 | -90.90 | -34.40 |
|
Earnings Per Share (Basic)
|
-4.66 | -2.75 | -2.25 | -3.35 | - |
|
Diluted EPS
|
-4.66 | -2.75 | -2.25 | -3.35 | - |
|
Weighted Average Shares
|
64.23 | 55.33 | 42.71 | 26.57 | - |
|
Diluted Weighted Avg Shares
|
64.23 | 55.33 | 42.71 | 26.57 | - |
|
Comprehensive Income
|
- | - | - | - | - |